Canadian Securities ExchangeThe Daily Bell

Anthony Tennyson on Medication-Assisted Treatments for Addiction

February 22, 2024Newly Listed on the CSE

(CSE:AWKN)

About This Video

Canadian Securities Exchange (CSE)’s Anil Mall recently caught up with Anthony Tennyson, CEO of Awakn Life Sciences Corp. (CSE:AWKN) to discuss the company's path to listing and how they are pursuing a mission to develop medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD) - a condition affecting approximately 51 million people in the US and key European markets and 285 million people globally.

Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.

thank you to our viewers who are tuning back into another newly listed on the csse clip this one's a little different here because the company awaken Life Sciences was previously listed on another exchange it's now listed on the Canadian Securities Exchange and we are speaking with Anthony Tenison who is the co-founder and CEO of awaken Life Sciences Corp it trades under the symbol a wkn Anthony welcome to csct TV I hope

you're doing well I am indeed it's good to speak to you and it's good to speak to your audience today excellent Anthony Let's you know I actually want to talk a little bit about alcohol addiction alcohol addiction treatment but before we jump into that let's why don't you give our viewers an introduction to awaken life sciences and the focus of your company yeah yeah I'm happy to so so we're a biotechnology

company we're in fact a late clinical stage biotechnology company developing medication assisted treatments for addiction with a near-term focus on alcohol use disorder which unfortunately is a condition that affects about 50 million people in the US Canada and the key European markets of UK Germany Italy France and Spain we have three core programs our lead program awk 001 we've completed phase two

we're targeting severe alcohol use disorder we achieved groundbreaking results in phase two people coming out to that trial they were abstinent so sober 2% of the time so they were sober 7 days a year in the active arm of the trial we got them to being abstinent or sober on average 86% of the time in the 6 months post treatment which is about three and a half times better than the

current standard of care for alkol use disorder we're in a very lucky position we're progressing that forward now into phase three in partnership with the UK Department of Health and we're expecting enrollment to start in in this current quarter we've got a a secondary program where we're working with the German pharmaceutical company and we're targeting the US market for alcohol use disorder and we've got a tertiary

program where we're working to repurpose MDMA to improve the pharmacokinetics of MDMA all of which we're focusing on Al use disorder in the near term and will broaden IE into other addictions in Zu course and So currently if I'm not mistaken you said you guys are in the clinical stages of this that's correct we're we're in late clinical stage so the program moving in start phase three

enrollment due to start this current quarter secondary program we're hoping to get into phase two in the US in in the medium term on our third program is is earlier stage it's it's an early stage got it now I want to get your Insight a little bit I'm I'm sure our audience as well you know a lot of the Focus right now when it comes to addiction goes into the fentone crisis

there's a lot of talk around that which is equally important but alcohol addiction has been around for centuries now and I want to get your insight into what current treatment looks like and so I think you know F first thing that is really important to understand with alcohol addiction is is the number of people that are affected really as I mentioned 50 million people in North America on key European markets

285 million people globally so this is a very big problem in the US specifically current treatments there's about 14 a half thousand clinics in the US treating alcohol use disorder on Direct costs to the Health Care System Medicare Medicaid payers 25 to 35 billion dollars a year most of that treatment is talk-based therapy only with pretty poor outcomes you're looking at at about a 75% relapse rate 12 months

post treatment so within 12 months of treatment 3/4s of people who are treat will have relapsed that results in only very very few people who suffer with this disease actually seeking treatment so in the US of the 29 million people that suffer with alcohol use disorder only 10% of those people seek treatment and of those people that seek treatment 3/4s have relapsed 12 months post treatment so there is a significant

treat and Gap or unmet medical need with this disease in the US and those Trends are the same in most other countries where most other developed economies where this disease is prevalent so now as you and your team are moving to to hopefully provide a solution to alcohol addiction treatment what are some of the challenges that you you come across and face well most some of the challenges

what what we're doing is is we're repurposing approved or soon to be approved drugs to be then used in combination with therapy to treat alcohol and use disorder the drugs that we're working with are currently scheduled so we're working with ketamine now that's okay ketamine is a is is an approved medicine it's already on label as a painkiller and as an anesthetic in most economies but we're also as I

mentioned at the front end of this interview we're also working with with MDMA so and what we're doing is we're using those drugs to essentially help us rewire the brain and to make therapy more effective and say in essence what we're doing is through a very short treatment course what we're doing with cming is 17 hours eight patients over four weeks terap therapy and Drug delivered together and that delivers

those results but what we find is there's there's a certain amount of inbuilt resistance in the addiction treatment industry now I'm not here to throw stones at any industry or anything along those lines but there are some Tye parts of the industry that quite like the revolving door that exists in the treatment for alcohol use disorder and so what we look what we see when we see

the addiction treatment industry in the US in particular with those 14 and a half th clinics training alcohal use disorder with a 75% failure reach but yet costing the system 25 to $35 billion a year what we see is we see an industry that requires disruption we see an opportunity to disrupt that industry but we know there's going to be resistance because there are incumbents that like the

industry operating the way that it does and so what we're doing and what we're setting about doing is bringing to Market therapies and Therapeutics that are significantly more effective than the incumbent treatments to enable us to disrupt the that large underperforming industry and really the core purpose is so that we can provide hope for individuals families and communities for whom those current treatments aren't working you know I I

think I think what you said there at the end really hits because I think I think everybody has or knows somebody that's been affected by alcohol addiction and you know at the end it it it does it's like a waterfall there are fames children affected by this so I'm glad to see that you know you and your team have that Focus Anthony I want to ask you a little bit

about your background how did you get into the space so I'm I'm not a scientist by any way shape or form I'm a technologist by training of a degree to Masters in technology I decided I want to know I have money worked coming at a university so I worked in banking for a number of years I left banking when the financial crisis occurred and I went to work in

Professional Services but and I worked for did a did about 10 years I'm based in Ireland in Dublin but I did 10 years three days a week based in Dublin when I was working in Dublin the financial district in Dublin is Che by jel with the North Inner City which is the most underprivileged part of irand and so I observed up close and personal the damage that alcohol opio heroin and

also gambling do to have done and continue to do to large parts of Irish Society then when I went to work in London did 10 years three days a week so on a plane and living in hotels and it started to get i' I've spoken about this publicly before it started to get a bit messy Wednesday nights turning into Saturday nights Etc as happens when you spend too much time traveling and so I

decided I had to get out of that that that lifestyle and and so that's why myself and my co-founders John held my CFO my co-founder who I know through a mutual acquaintance or knew through a mutual acquaintance we decided to come together to bring the benefits of psychedelics to Bear to solve a problem that I was brushing up against that's destroyed lots of large parts of Irish

society and many parts of other societies globally and what we set out to do was to psychedelics to Bear to make therapy more effective in solving this large intractable problem that destroys individuals families at I want to thank you for sharing a little bit of your personal Journey as well what about some of your your key team members I know you mentioned your co-founder there you

want to maybe talk a little bit about some of your team members that you know you've brought on board to make sure that this company and you know your treatment succeeds yes so we're lucky enough to have a very very good team I'll just mention a few of them just in the interest of time but I've got my co-founder a John H who who's a Canadian very familiar with the Canadian markets

as so that's key for for your investors or not for your investors for your audience to understand is we're very proximate to to can the Canadian investor base on the science side we've got a very very good team that's led by Professor David nut who is a world Authority in the addiction space he was the former head of the European Brain Council he's had a department

in Imperial College London in the psychopharmacology department and he works for us part-time and he is one of the top three researchers globally in the area of addiction and he is the top researcher in the use of psychedelic drugs in combination with therapy to treat addiction so David is our chief scientific officer we've got a good team of special advisers key one for for your audience probably is Professor

Barbara Mason she's head of the scripts Institute in California and she's one of the US's leading researchers in the area of addiction and her and David would have worked together on bringing drugs to Market and getting FDA approval in the addiction space over many years so we've got a a really lean focused team with experience in Canadian Capital markets with experience in the Psychedelic space and the addiction

space and with great experience with interacting with Regulators UK Europe and very very importantly in the US because that's really the core market for us is beginning to work now with the FDA and to initiate research to get us into Market in the US inine course because that's where the big that's where the biggest need is but it is a commercial entity and that's where the biggest commercial opportunity also

exists as well so so you're out there trying to provide a solution to a problem that's affecting a lot of people you have a strong team you've you've just listed on the CSE of course you were you're previously listed company but you're on the CSC now what are some of the Milestones that our viewers can expect and look out from you and your team in the next four to six months sure

so I think what's really important for your viewers and the team to understand is we've got data we've got efficacy safety proven efficacy proven and we've got data we're in the clinic and we're actually at late clinical stage so our lead program where we're repurposing re mamine to be used in combination with therapy to treat severe alcohol use disorder phase two completed phase three due to start this current quarter so

enrollment two to start this current quarter that trial is a 280 person trial it's been run at extremely low cost because the UK Department of Health are funding most of us so that Tri costs us 800,000 Sterling and the key milestone for us is enrollment to start this quarter and then to run that trial through the course of this year and next year our secondary program where we're

working with the German pharmaceutical company to repurpose s ketamine so the s aner of Rim Academy into an oral 10 film where we have appropriate IP protection in place or a formulation and method of use key milestone for us is to seek a pre meeting to get approval from the FDA to go strange into late clinical or fa late phase two so to go to phase 2 b

and to then complete that or get that feedback from the pre meeting and then to start a phase 2 B trial so we're going to seek that pre- meeting in the near term we didn't to have feedback in H1 this year and then ideally start that Lake clinical stage trial in H2 this year and then the next Milestone is we're working with calent one of the world's largest drug Dev manufacturing

distribution companies to repurpose MDMA into an oral disintegrating tablish for sublingual delivery and we believe we can significantly improve the pharmacokinetics of MDMA assisted Psychotherapy thereby improving the unity econom ICS when it comes to actual Healthcare setting and the key Milestones are should have results from an animal study where we can compare and contrast to PK traditional MDMA versus our formulation of MDMA and if that's promising then it would be to seek to

get into the clinic as soon as possible through the FDA so data from that animal study H1 this year and that idity getting into the clinic H2 or H H2 this year or H1 Nick well s well I I I I want to thank you for taking the time to you know educate myself a little bit and talk to our audience about this crisis that's happening and how awaken Life Sciences

is working towards providing Solutions where can we direct our viewers to to you know obviously sign up for your press release read up on your your trials and of course reach out to you and your team should they want more information so if they want to reach out to to me it's Anthony awaken life sciences.com that's awaken can spell a w a n Lifesciences decom just drop me an

email I'm more than happy to to connect have a conversation and anyone who wants to find out more about the company just visit our website awaken life sciences.com go into the investor relations section there our corporate deck is there all our all our historic news is there and then they can sign up for for our comms as well and they'll receive all the all the PRS as we push

them in excellent Anthony I look forward to hosting you on in the next let's say six months where we can provide our audience with an other update again to everybody watching you've been listening to Anthony Tennyson who is the co-founder and CEO of awaken Life Sciences Corp on the CSC now under the symbol awk and of course I'm going to end it off by saying you know if you are

struggling and dealing with any sort of addiction whether it might be food drugs or specifically alcohol addiction there are people out there to help talk to somebody I know it's easy to say speak talk to someone but I think a lot of people are in the same boat at this time I would echo echo that to as well Anthony again thank you so much and

you have a great day thank you very much it's been a

pleasure

More Newly Listed on the CSE

See them all

Tiger Financial (CSE:BANQ)From Cash to DigitalOct 27, 2026
Caldwell-Lazard CorePlus Infrastructure Fund (CSE:CPIF)Sep 14, 2026
SECUR3D Holdings (CSE:SRD)AI-Powered Brand ProtectionSep 8, 2026
Secur3D Holdings (CSE:SRD)AI-Powered Brand & IP ProtectionAug 20, 2026